Lidan Hu is a Distinguished Associate Research Fellow at the National Clinical Research Center of the Children's Hospital affiliated with Zhejiang University School of Medicine. She earned her PhD from Tsinghua University in 2020, where she also completed her postdoctoral research. Her work focuses on multi-level disease models (stable cell lines/iPSC/organoids/mice) and multi-omics analysis to explore the pathogenesis of genetic diseases, including kidney disease, progeria, and ophthalmology, with an emphasis on liquid–liquid phase separation, protein aggregates, and RNA granule metabolism regulation. She has published extensively, with notable contributions to journals such as Nature, Protein & Cell, and Cell Communication and Signaling. Dr. Hu is a member of several academic committees, including the Biochemistry and Molecular Pharmacology Committee of the Chinese Pharmacological Society and the Zhejiang Neuroscience Society. Her research aims to develop targeted drug screening platforms and precise prevention and treatment strategies for genetic diseases.
Lidan Hu is a Distinguished Associate Research Fellow at the National Clinical Research Center of the Children's Hospital affiliated with Zhejiang University School of Medicine. She earned her PhD from Tsinghua University in 2020, where she also completed her postdoctoral research. Her work focuses on multi-level disease models (stable cell lines/iPSC/organoids/mice) and multi-omics analysis to explore the pathogenesis of genetic diseases, including kidney disease, progeria, and ophthalmology, with an emphasis on liquid–liquid phase separation, protein aggregates, and RNA granule metabolism regulation. She has published extensively, with notable contributions to journals such as Nature, Protein & Cell, and Cell Communication and Signaling. Dr. Hu is a member of several academic committees, including the Biochemistry and Molecular Pharmacology Committee of the Chinese Pharmacological Society and the Zhejiang Neuroscience Society. Her research aims to develop targeted drug screening platforms and precise prevention and treatment strategies for genetic diseases.